Correspondence 0001213900-24-107650 from MAINZ BIOMED N.V. (MYNZ) (CIK 0001874252) (MYNZ)
MAINZ BIOMED N.V. (MYNZ) (CIK 0001874252)
Date: Dec. 11, 2024 · CIK: 0001874252 · Accession: 0001213900-24-107650
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282993
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Finance 100 F Street, NE Washington, D.C. 20549 Re: Mainz Biomed N.V. Registration Statement on Form F-1 (Registration No. 333-282993)
Dear Ms. Sheppard:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned, as placement agent in connection with the above referenced Registration Statement relating to the offer and issuance by the Registrant of certain of its securities, hereby joins the Registrant’s request that the effective date of the Registration Statement be accelerated so that it shall be declared effective at 5:00 PM Eastern Time on Thursday, December 12, 2024, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Act, we wish to advise you that the placement agent has distributed as many copies of the Preliminary Prospectus, dated December 11, 2024, to investors, dealers, institutions and others as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
This is to further advise you that the placement agent has and will continue to comply with Rule 15c2-8 of the Securities Exchange Act of 1934, as amended, with regard to the Preliminary Prospectus and any amended Prospectus.
If you require any additional information with respect to this letter, please contact Ali Panjwani of Pryor Cashman LLP at (212) 326-0820.
Very truly yours,
MAXIM GROUP LLC
Show Raw Text
CORRESP
1
filename1.htm
MAXIM GROUP LLC
300 Park Avenue
New York, New York 10022
December 11, 2024
VIA EDGAR
Tamika Sheppard
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Finance
100 F Street, NE
Washington, D.C. 20549
Re: Mainz Biomed N.V.
Registration Statement on Form F-1 (Registration
No. 333-282993)
Dear Ms. Sheppard:
Pursuant to Rule 461 under the Securities Act
of 1933, as amended (the “Securities Act”), the undersigned, as placement agent in connection with the above referenced
Registration Statement relating to the offer and issuance by the Registrant of certain of its securities, hereby joins the Registrant’s
request that the effective date of the Registration Statement be accelerated so that it shall be declared effective at 5:00 PM Eastern
Time on Thursday, December 12, 2024, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Act, we wish to
advise you that the placement agent has distributed as many copies of the Preliminary Prospectus, dated December 11, 2024, to investors,
dealers, institutions and others as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
This is to further advise you that the placement
agent has and will continue to comply with Rule 15c2-8 of the Securities Exchange Act of 1934, as amended, with regard to the Preliminary
Prospectus and any amended Prospectus.
If you require any additional information with
respect to this letter, please contact Ali Panjwani of Pryor Cashman LLP at (212) 326-0820.
Very truly yours,
MAXIM GROUP LLC
By:
/s/ Ritesh M. Veera
Name:
Ritesh M. Veera
Title:
Co-Head of Investment Banking